BELLEVUE, Wash., Jan. 22, 2014 (GLOBE NEWSWIRE) -- mCig, Inc. (OTCQB:MCIG) is pleased to announce the formation of a Medical Advisory Board to help oversee the company's strategy and assist in the preparation to enter new markets. The first addition to the board is Dr. Khary Bryan, the official representative of Cannatest in the New England States.
Dr. Khary Bryan Biography:
Dr. Khary Bryan is a 2001 graduate of the Philadelphia College of Pharmacy. During the six years of Doctor of Pharmacy training, his personal goal was to learn different methods of disease prevention in addition to the pharmaceutical management of disease. It was during this time he discovered the role of nutraceuticals and functional foods in the prevention and treatment of disease, although his parents exposed him to herbal medicine and a disease prevention lifestyle from an early age. In 2010 Dr. Bryan became aware of the endocannabinoid system and began to attend cannabis industry conferences in order to gain more knowledge. In 2011 he established a relationship with the cannabinoid analysis company Cannatest and in 2012 began to represent Cannatest in the medical cannabis of New England States. In this role he educates legal caregivers and patients about the science of the endocannabinoid system, cannabis plant, and High Performance Thin Layer Chromatography cannabinoid analysis method. Dr. Bryan also works as a community pharmacist in Connecticut and is a member of the International Cannabinoid Research Society, Canadian Consortium for the investigation of Cannabinoids and the Society of Cannabis Clinicians.
Commenting on his appointment Dr. Bryan stated: "I am eager to lead the mCig Medical Advisory Board and contribute to the momentum of the company through the continued enhancement of vaporization efficiency. Additionally, I envision the mCig device as a delivery method for therapeutic plant secondary metabolite vapor and will be working toward this goal."
The company has previously stated it is developing a new product codenamed: "VITA". The company expects to update its shareholders on the progress of this new division in the coming weeks. This product will provide entry into a totally new market for mCig, Inc.
As part of this transaction Mr. Paul Rosenberg mCig CEO has committed to cancel an equal amount of his shares against any shares issued to Dr. Khary Bryan.
About mCig, Inc.
mCig, Inc. (OTCQB:MCIG) is a technology company focused on two long-term secular trends sweeping the globe: (1) The decriminalization and legalization of marijuana for medicinal or recreational purposes (2) The adoption of electronic vaporizing cigarettes (commonly known as "eCigs") by the world's 1.2 Billion smokers. The company manufactures and retails the mCig – a purpose built loose leaf eCig retailing at only $10. Designed in the USA – the mCig provides a superior smoking experience by heating plant material, waxes, and oils delivering a smoother inhalation experience. See more at: http://www.mcig.org/
The company believes that a well regulated marijuana industry is emerging as more states follow the lead of Washington and Colorado in legalizing marijuana. A similar trend is developing within the eCig industry following the first acquisition of an electronic cigarette brand (Blucigs) by a traditional tobacco company Lorillard Inc. for $135 million. Wells Fargo analyst Bonnie Herzog estimates that eCig sales may rise from $1 Billion in 2013 to $10 billion over the next three years.
mCig, Inc. (OTCQB:MCIG) has positioned itself as a first mover at the intersection of these two trends and hopes to create shareholder value by making the mCig one of the leading choices for electronic consumption of plant material. - See more at: http://www.mcig.org/investors/investor-opportunity-subpage/
Safe Harbor Statement
Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, and future product commercialization; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies.
CONTACT: Paul Rosenberg CEO (425)462-4219Source:mCig, Inc.